Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Novo Nordisk A/S shares fell over 4% premarket Friday, heading for lows last seen in early August, amid concerns over pricing ...

The Centers for Medicare & Medicaid Services (CMS) said Friday that it had selected another 15 drugs for its second round of ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

The stock is down 3%, or $2.81, to $80.26 in premarket trading.Stay Ahead of the Market:Discover outperforming stocks and invest smarter with ...

The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional ...

Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating ...

The latest buzz around the popular weight loss drugs Ozempic, Mounjaro and Wegovy is to reduce the doseage to avoid the ...

Those in the jab trials, however, kept off between 10 and 25 per cent of their body weight over the same timeframe, depending ...